Document Detail

Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers.
MedLine Citation:
PMID:  18597648     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: Our group has previously show that interindividual variability in CYP2D6 hydroxylation capacity was related to personality differences in cognitive social anxiety. Thus, we aimed to analyze whether this relationship between personality and CYP2D6 phenotype and genotype was found in a similar population of healthy volunteers from a different latitude and culture by using the same methodology. METHODS: A total of 253 university students and staff from Havana Psychiatric Hospital and Calixto García Medical School in Cuba completed the Karolinska Scales of Personality (KSP), and were evaluated on debrisoquine hydroxylation capacity and CYP2D6 genotypes. KSP scores were compared between four groups, divided according to their CYP2D6 metabolic capacity: one of poor and three of extensive metabolizers. Furthermore, KSP scores were compared between another four different groups divided according to their number of CYP2D6 active genes: zero, one, two, and more than two. RESULTS: In Cubans, the differences in cognitive social anxiety-related personality traits across the four CYP2D6 hydroxylation capacity groups were strikingly similar to those found in Spaniards. These differences also came out to be significant for psychic anxiety (p = 0.02) and socialization (p = 0.02). The same pattern of results obtained for the subscales of psychic anxiety, socialization, psychasthenia and inhibition of aggression with regard to phenotype in both the Cuban and Spanish studies were seen with regard to CYP2D6 genotypes. CONCLUSIONS: Corroborating these results further strengthens evidence of the relationship between CYP2D6 metabolic capacity and personality. In this population of healthy Cuban volunteers, the CYP2D6 hydroxylation capacity was related to the degree of anxiety and socialization. These results support the postulated reduction of serotonin in CYP2D6 poor metabolizers, which may be associated with a cluster of behavioral traits (e.g., anxiety, impulsivity). Thus, research is warranted to determine CYP2D6 functional implications for interindividual differences in vulnerability to neuropsychiatric diseases and drug response.
Idilio González; Eva M Peñas-Lledó; Bárbaro Pérez; Pedro Dorado; Mayra Alvarez; Adrián LLerena
Related Documents :
15053708 - Thin slices of behavior as cues of personality and intelligence.
16405638 - The relation between salivary cortisol, callous-unemotional traits, and conduct problem...
6578538 - Psychological and behavioral characteristics of normal-weight bulimics and normal-weigh...
17638458 - The relations of motivational traits with workplace deviance.
24003588 - The good-in-bed effect: college students' tendency to see themselves as better than oth...
22347768 - Performance-based contracting and the moderating influence of caseworker role overload ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Pharmacogenomics     Volume:  9     ISSN:  1744-8042     ISO Abbreviation:  Pharmacogenomics     Publication Date:  2008 Jul 
Date Detail:
Created Date:  2008-07-03     Completed Date:  2008-08-25     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100897350     Medline TA:  Pharmacogenomics     Country:  England    
Other Details:
Languages:  eng     Pagination:  833-40     Citation Subset:  IM    
Hospital Psiquiátrico de La Habana, Cuba.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anxiety / genetics
Cytochrome P-450 CYP2D6 / genetics*,  metabolism
Debrisoquin / pharmacokinetics
Middle Aged
Personality / genetics*
Personality Assessment
Polymorphism, Genetic*
Reg. No./Substance:
1131-64-2/Debrisoquin; EC P-450 CYP2D6

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Transdermal lovastatin enhances fracture repair in rats.
Next Document:  Genetic variants in FKBP5 affecting response to antidepressant drug treatment.